European Meeting on HIV & Hepatitis 2018

Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assaysing next-generation sequencing- Robert Ehret

Slideset

HIV

Viral Hepatitis and Liver Disease

The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms- Stephanie Popping

Slideset

HIV

Viral Hepatitis and Liver Disease

The current status of PrEP in Europe- Pep Coll, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Influence of resistance in the future- Richard Harrigan, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le Hingrat

Slideset

HIV

Viral Hepatitis and Liver Disease

A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi

Slideset

HIV

Viral Hepatitis and Liver Disease

Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen

Slideset

HIV

Viral Hepatitis and Liver Disease

Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro

Slideset

HIV

Viral Hepatitis and Liver Disease

Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen

Slideset

HIV

Viral Hepatitis and Liver Disease

Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP

Slideset

HIV

Viral Hepatitis and Liver Disease

Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati

Slideset

HIV

Viral Hepatitis and Liver Disease

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

Slideset

HIV

Viral Hepatitis and Liver Disease

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Reduced drug regimens- Andrea De Luca, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

European Meeting on HIV & Hepatitis 2018

The HIV epidemic in CEE countries- Oana Săndulescu, MD, PhD

How would the epidemic evolve in the future- David van de Vijver

Long acting HIV drugs for prevention: what are the data?- Pep Coll, MD

HIV transmission in the migrant population- Dimitrios Paraskevis, PhD

Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assaysing next-generation sequencing- Robert Ehret

The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms- Stephanie Popping

The current status of PrEP in Europe- Pep Coll, MD

Influence of resistance in the future- Richard Harrigan, MD

A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le Hingrat

A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhD

Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi

Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen

Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro

Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen

Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD

Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP

Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD

Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

Reduced drug regimens- Andrea De Luca, MD

What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD